stoxline Quote Chart Rank Option Currency Glossary
  
Aadi Bioscience, Inc. (AADI)
2.34  -0.03 (-1.27%)    03-28 16:00
Open: 2.38
High: 2.4491
Volume: 345,325
  
Pre. Close: 2.37
Low: 2.33
Market Cap: 57(M)
Technical analysis
2024-03-28 4:49:26 PM
Short term     
Mid term     
Targets 6-month :  2.88 1-year :  3.36
Resists First :  2.47 Second :  2.88
Pivot price 2.16
Supports First :  2.09 Second :  1.86
MAs MA(5) :  2.25 MA(20) :  2.16
MA(100) :  2.79 MA(250) :  4.94
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  84 D(3) :  73.1
RSI RSI(14): 59.8
52-week High :  8.64 Low :  1.54
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ AADI ] has closed below upper band by 4.9%. Bollinger Bands are 67.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 56 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.45 - 2.46 2.46 - 2.48
Low: 2.3 - 2.31 2.31 - 2.33
Close: 2.32 - 2.34 2.34 - 2.36
Company Description

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Headline News

Mon, 18 Mar 2024
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Sun, 17 Mar 2024
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin ... - PR Newswire

Fri, 15 Mar 2024
Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2023 Earnings Call Transcript - Yahoo Finance

Wed, 13 Mar 2024
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Wed, 13 Mar 2024
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update - PR Newswire

Wed, 13 Mar 2024
Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 25 (M)
Shares Float 17 (M)
Held by Insiders 12.4 (%)
Held by Institutions 52.8 (%)
Shares Short 949 (K)
Shares Short P.Month 1,140 (K)
Stock Financials
EPS -2.45
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.28
Profit Margin -270.1 %
Operating Margin -280.1 %
Return on Assets (ttm) -28.4 %
Return on Equity (ttm) -50 %
Qtrly Rev. Growth 21 %
Gross Profit (p.s.) 0
Sales Per Share 0.99
EBITDA (p.s.) -2.93
Qtrly Earnings Growth 0 %
Operating Cash Flow -60 (M)
Levered Free Cash Flow -38 (M)
Stock Valuations
PE Ratio -0.96
PEG Ratio 0
Price to Book value 0.54
Price to Sales 2.35
Price to Cash Flow -0.97
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android